Owlet, Inc.

Owlet, Inc. Annual Report - Investor Summary

1. Business Overview Owlet, Inc. is a health technology company best known for its Smart Sock, a smart baby monitor that tracks a baby's heart rate and oxygen levels. In the fiscal year ending December 31, 2025, Owlet navigated a challenging market. The company faced significant legal expenses and prioritized capital preservation, yet still advanced product development and market expansion. Despite operational headwinds, Owlet continued investing in its core technology and exploring new growth avenues.

2. Financial Performance

• Revenue: Owlet reported revenue of approximately $55 million for 2025, a 10% decrease from $61 million in 2024. Increased competition and regulatory delays impacting new product launches primarily drove this decline.
• Net Loss: Owlet's net loss widened to $40 million in 2025, up from $35 million in 2024. This widening loss reflects increased legal costs and continued investment in research and development.
• Operating Expenses:
  • Research and Development (R&D): R&D expenses decreased to $15 million in 2025 from $18 million in 2024, suggesting a slight scaling back or completion of certain development phases.
  • Selling and Marketing (S&M): Selling and Marketing (S&M) expenses remained substantial at $20 million in 2025, nearly flat from $21 million in 2024, as the company continued efforts to capture market share.
  • General and Administrative (G&A): General and Administrative (G&A) expenses rose to $18 million in 2025 from $15 million in 2024, primarily due to increased legal fees from ongoing litigation.
• Customer Concentration: A single large retail customer generated approximately 25% of Owlet's sales revenue in both 2025 and 2024. The top three customers also accounted for about 40% of the company's accounts receivable as of December 31, 2025. This high concentration poses a considerable risk: losing even one major customer could materially impact sales and cash flow.

3. Risk Factors

• Regulatory Hurdles: As a health technology company, Owlet faces significant regulatory risks, particularly concerning FDA clearance and product classification. Changes in regulatory requirements or approval delays could severely impact product launches and market access.
• Intense Competition: The smart baby monitoring market is highly competitive, with established players and new entrants. Owlet must continuously innovate and differentiate its products to maintain market share against rivals such as Nanit, Snuza, and traditional monitor manufacturers.
• Customer Concentration: Reliance on a few large customers means the loss of any one, or a significant reduction in their orders, could disproportionately impact Owlet's financial performance.
• Ongoing Litigation: Multiple pending lawsuits present substantial financial and reputational risks. Adverse outcomes could lead to significant monetary damages, legal fees, and damage to the company's brand and investor confidence.
• Liquidity and Debt Repayment: With a net loss and substantial debt maturing in 2025, Owlet faces liquidity challenges. Its ability to repay or refinance its WTI Loan and ABL Line of Credit depends on improving operational cash flow or securing additional financing, which may not be available on favorable terms.
• Shareholder Dilution: The large number of outstanding warrants and convertible preferred stock could significantly dilute existing common shareholders' ownership and earnings per share if converted or exercised.

4. Management Discussion & Analysis (MD&A) Highlights

• Challenges - Legal Battles: Owlet faced multiple ongoing lawsuits. These include securities class actions (e.g., "Butala v. Owlet Inc." and "Cherian v. Owlet Inc.") alleging violations of securities laws (Sections 10b and 14a, pertaining to misleading statements and proxy solicitations) for both 2024 and 2025. Shareholders also initiated derivative lawsuits (e.g., "Janet Vargas Derivatively on Behalf of Nominal Defendant Owlet Inc." filed August 2024, and "Nathan Capleton Derivatively on Behalf of Nominal Defendant Owlet Inc." filed October 2024), suing company management on behalf of Owlet itself. These legal proceedings are costly, divert management's attention, and risk substantial financial penalties or settlements.
• Wins - Capital Raising: Owlet successfully raised capital through a Public Stock Offering in October 2025, generating approximately $25 million in gross proceeds. This followed a Private Placement of Convertible Preferred Stock Series B in February 2024, which brought in $15 million. These capital infusions were critical for funding operations and managing liquidity, though the public offering also diluted shareholder ownership.

5. Financial Health

• Cash Reserves: As of December 31, 2025, Owlet reported total cash and cash equivalents of $30 million, which included $5 million held in Litigation Settlement Escrow and $2 million in Cash Collateral accounts. This marks a decrease from $45 million at the end of 2024, indicating a burn rate that necessitates careful cash management.
• Debt Obligations: Owlet carries significant debt:
  • A "WTI Loan Facility" (a term loan for growth-stage companies) has an outstanding principal of $12 million, established in September 2024 and maturing in July 2025.
  • An "ABL Line of Credit" (Asset-Based Lending, a revolving credit facility secured by assets like inventory and receivables) has $8 million drawn, established in September 2024 and maturing in September 2025. These obligations require substantial near-term interest and principal repayments, posing a liquidity challenge if operational cash flow does not improve.
• Equity Structure and Potential Dilution: Owlet's capital structure includes various equity instruments: Convertible Preferred Stock (Series A and B), Redeemable Common Stock, and regular Common Stock. Additionally, multiple types of warrants remain outstanding (SBG Public, SBG Private, Series A, Series B, Titan, and SVB Warrants). The potential exercise of these warrants could significantly increase outstanding common shares, leading to dilution for existing shareholders and potentially depressing the stock price.

6. Future Outlook & Strategy

• Strategy: Owlet's strategy focuses on navigating regulatory challenges, managing liquidity, and continuing product innovation. The company aims to expand product offerings beyond the Smart Sock and explore new distribution channels, potentially including direct-to-consumer models and partnerships with healthcare providers. Cost control measures and efficient capital deployment are also key strategic priorities, given current financial performance. Owlet has indicated plans to seek further regulatory clearances for its products, which could unlock new market opportunities.
• Immediate Outlook: Owlet's immediate future outlook depends heavily on its ability to manage debt maturities in mid-to-late 2025 and achieve positive cash flow from operations.

7. Competitive Position Owlet operates in the rapidly evolving smart baby monitoring market, positioning itself as a leader in vital sign tracking with its Smart Sock technology. Its key competitive advantages include early market entry and brand recognition. However, it faces strong competition from companies offering similar vital sign monitoring (e.g., Nanit, Snuza) and a broader range of smart nursery products. Owlet's ability to differentiate through innovation, clinical validation, and regulatory approvals will prove crucial for maintaining its competitive edge. The baby tech market continues to grow, driven by increasing parental demand for smart monitoring solutions and data-driven insights into infant health. However, it also faces evolving regulatory scrutiny, particularly concerning medical device classifications and data privacy (e.g., HIPAA in the US).